Diabetic Nephropathy

Dr. Shahidul Islam, MD, Professor, PhD, Department of Biochemistry, University of KwaZulu-Natal. He is an expert in diabetes and has achieved a number of awards including the International Endocrine Society. He has over 30 years of research and teaching experience, has published in 20 international peer reviewed journals, is an “Editor-in-Chief” of the “World Journal of Diabetes”. Prof. Islam has been selected as one of the Global Top 2% researcher by Mandeley during 2019 and as one of the Global Top 0.016% researcher in the area of Experimental Diabetes Mellitus by Expert Escape during 2021. Prof. Islam has published 14 peer reviewed book chapters, more than 200 research articles in the international peer reviewed journals including 11 reviews since 2004. He has successfully supervised the research projects of over 45 Postdoctoral Fellows and students.

• 1. Challenges in Pathogenesis, Diagnosis, and Treatment of Diabetic Nephropathy: An Update2. Roles and Cross Talks of Macrophages in Diabetic Nephropathy3. AMPK Allostery: A Therapeutic Target for the Management or Treatment of Diabetic Nephropathy4. Autophagy Regulation as Therapeutic Target for Diabetic Nephropathy5. MicroRNA and Circular RNA as New Generation Therapeutic Targets in the Management of Diabetic Nephropathy6. Caveolin-1 in the Pathogenesis and as a Therapeutic Target for Diabetic Nephropathy7. Exosome, a Major Extracellular Vesicle, as a Therapeutic Strategy for Diabetic Nephropathy8. Deletion of Smad3 as a Therapeutic Target for the Prevention of Renal Fibrosis and Inflammation in Diabetic Nephropathy9. Myokines and Mitochondrial DNA as Some Novel Therapeutic Targets for the Management of Diabetic Nephropathy10. Activation of Nrf2 Signaling Pathway as a Therapeutic Target for the Amelioration of Diabetic Nephropathy11. YY1 as a Novel Therapeutic Target for the Prevention of Renal Fibrosis in Diabetic Nephropathy12. Microbubbles and Ultrasound Mediated Gene Delivery as a Novel Therapeutic Approach for the Treatment of Diabetic Nephropathy13. Human Antigen R as a Novel Therapeutic Target for the Management of Diabetic Nephropathy14. Farnesoid X Receptor as a Potential Therapeutic Target for the Treatment of Diabetic Kidney Disease15. SET7, a Lysine-Specific Methyl Transferase as an Epigenetic Target for the Treatment of Diabetic Nephropathy16. DNA Methyltransferase 1 as a Therapeutic Target for Attenuating Diabetic Nephropathy17. Roles of Non-Coding RNA CYP4B1-PS1-001 in Regulating the Proliferation of Renal Fibrosis in Diabetic Nephropathy18. Bioactive Pure Phytochemicals in the Management and Treatment of Diabetic Nephropathy19. Oxidative Stress and Antioxidant Defense as a Target for the Management of Diabetic Kidney Disease20. Roles of mTOR Inhibitors in the Management of Renal Cancer and Diabetic Kidney Disease